Novo Nordisk A/S (NYSE:NVO) Stock Rating Upgraded by Pareto Securities

Novo Nordisk A/S (NYSE:NVO) was upgraded by research analysts at Pareto Securities from a “hold” rating to a “buy” rating in a research note issued on Monday, The Fly reports.

A number of other analysts have also weighed in on NVO. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 target price on the stock in a research note on Monday, July 15th. UBS Group reiterated a “buy” rating and issued a $355.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, June 19th. Barclays upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price target on the stock in a research note on Tuesday, June 11th. Credit Suisse Group upgraded shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. Finally, Deutsche Bank lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price target on the stock. in a research note on Thursday, June 20th. One analyst has rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $111.58.

Shares of NVO stock traded down $0.31 during trading hours on Monday, reaching $48.41. 6,574 shares of the stock were exchanged, compared to its average volume of 1,780,926. The stock has a fifty day moving average price of $49.84. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.96 and a quick ratio of 0.66. Novo Nordisk A/S has a 12-month low of $41.23 and a 12-month high of $52.83. The stock has a market cap of $119.01 billion, a price-to-earnings ratio of 19.21, a P/E/G ratio of 2.23 and a beta of 0.60.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Friday, May 3rd. The company reported $0.66 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.04. Novo Nordisk A/S had a net margin of 33.60% and a return on equity of 78.28%. The firm had revenue of $4.46 billion for the quarter, compared to analyst estimates of $4.35 billion. As a group, research analysts predict that Novo Nordisk A/S will post 2.43 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the business. Clearbridge Investments LLC boosted its holdings in shares of Novo Nordisk A/S by 42.3% in the first quarter. Clearbridge Investments LLC now owns 1,160,942 shares of the company’s stock valued at $60,729,000 after acquiring an additional 344,989 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Novo Nordisk A/S by 11.4% in the first quarter. Janus Henderson Group PLC now owns 247,811 shares of the company’s stock valued at $12,963,000 after acquiring an additional 25,382 shares during the period. Hartwell J M Limited Partnership boosted its holdings in shares of Novo Nordisk A/S by 7.2% in the first quarter. Hartwell J M Limited Partnership now owns 10,400 shares of the company’s stock valued at $544,000 after acquiring an additional 700 shares during the period. GYL Financial Synergies LLC acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at approximately $1,090,000. Finally, Traynor Capital Management Inc. boosted its holdings in shares of Novo Nordisk A/S by 1.1% in the first quarter. Traynor Capital Management Inc. now owns 71,706 shares of the company’s stock valued at $3,750,000 after acquiring an additional 810 shares during the period. Institutional investors own 7.12% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: Why do companies pay special dividends?

The Fly

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.